Q2 2019

US BUSINESS NEWS / Q2 2019 27 , Adriana Herrera Appointed Senior Vice President, Americas Commercial Oncology at Eisai Inc. Eisai Inc., theU.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced the immediate appointment of AdrianaHerrera as Senior Vice President, Americas Commercial Oncology. Adriana Herrera will be responsible for developing and implementing the commercial strategy to accelerate the growth of Eisai’s oncology business in the Americas region. She will lead the oncology commercial organization, bringing together all internal stakeholders and cross-functional teams to provide seamless and integrated service delivery to customers and patients. “We welcome Adriana to our executive leadership team to steer our Oncology business through its next exciting phase of growth,” said Paul Hawthorne, Executive Vice President & Chief Commercial Officer of Eisai Inc. “She has excelled in launching oncology brands, developing disease awareness initiatives, creating market access strategies, and leading highly successful teams throughout her career. Her experiences, enthusiasm and personal commitment to patients align well with Eisai’s goal of Breaking Through to address some of society’s most difficult healthcare challenges.” Prior to joining Eisai, Herrera spent 12 years at Novartis Oncology, where she most recently served as Vice President, Global Disease Lead Lung Cancer, responsible for the global commercialization of various late- stage assets and in-line targeted therapies. She held previous roles of increasing responsibility in marketing, sales and operations at Novartis, as well as Bristol Myers Squibb, where she initially started her career in the industry. Herrera earned a Master of Business Administration degree from Columbia Business School in New York, and a Master of Public Health degree from the Mailman School of Public Health at Columbia University. She holds a Bachelor of Arts degree in Biology from Rutgers University in New Jersey. “Eisai continues to work tirelessly to improve outcomes for oncology patients through its innovative products, unique pipeline, and focus on immuno-modulation,” said Herrera. “The company’s commitment to its human health care (hhc) mission and patient- centricity strongly resonate with my personal values. I am excited to join Eisai and make a difference for patients and their families.” Over the past three decades, Eisai has been committed to the discovery and development of small molecules for the treatment of various difficult-to-treat cancers. The company’s current focus in oncology centers on tumor microenvironment modulation, the inhibition of pathways that inactivate the immune system, and cancer genomics. To learn more about Eisai’s global oncology business, please visit Eisai.com. Eisai will be showcasing its robust pipeline at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31-June 4, where the company will present 11 posters across multiple tumor types, including endometrial carcinoma.